Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kenneth Berger

Pulmonary Disease New York, NY Medical Doctor

NPI 1659365880 CMS profile 524285

400 E 34Th St, New York, NY 10016

Open in the dashboard

General payments

$126,246

87 records reported · program years 2019–2025

Research payments

$10,967

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kenneth Berger of New York, NY is reported in the CMS Open Payments database as having received $126,246 across 87 general payments and $10,967 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

11 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $239 2
2024 General $18 1
2023 General $429 2
2022 General $8,362 9
2022 Research $1,750 4
2021 General $39,919 13
2021 Research $1,250 1
2020 General $25,893 15
2020 Research $6,283 3
2019 General $51,387 45
2019 Research $1,684 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kenneth Berger
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Kenneth Berger were reported at $239. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Kenneth Berger Pulmonary Disease median Middle half National median
2019 $51,387 $377 $109–$1,340 $163
2020 $25,893 $230 $56–$907 $114
2021 $39,919 $269 $68–$1,072 $132
2022 $8,362 $390 $100–$1,457 $149
2023 $429 $419 $114–$1,659 $160
2024 $18 $476 $123–$1,818 $164
2025 $239 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $93,863 68 payments
  2. Sanofi US Services Inc. $17,370 5 payments
  3. Sanofi-Aventis U.S. LLC $8,083 2 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $3,800 3 payments
  5. Amicus Therapeutics, Inc. $2,679 1 payment
  6. Pfizer Inc. $239 2 payments
  7. Spark Therapeutics, Inc. $166 4 payments
  8. Sumitomo Pharma America, Inc. $47 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $109,225 32 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $10,301 11 payments
  3. Travel and Lodging $5,084 24 payments
  4. Food and Beverage $1,637 20 payments
Products named General payments · program years 2019–2025
  1. LUMIZYME Genetic Disease $35,032 21 payments
  2. NO PRODUCT DISCUSSED $17,369 9 payments
  3. LUMIZYME Rare Disease Genetics $17,088 18 payments
  4. DISEASE STATE $16,764 14 payments
  5. XENPOZYME $4,084 5 payments
  6. ELAPRASE $3,400 2 payments
  7. NURTEC ODT $239 2 payments
  8. GEMTESA $47 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Genzyme Corporation $5,749 11 payments
  2. Spark Therapeutics, Inc. $5,218 1 payment

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record